Hormone Receptor Expression and Activity for Different Tumour Locations in Patients with Advanced and Recurrent Endometrial Carcinoma

LUIJTEN, Maartje M W, van Weelden Willem JAN, Roy I LALISANG, Johan BULTEN, Kristina LINDEMANN, Heleen J VAN BEEKHUIZEN, Hans TRUM, Dorry BOLL, Henrica M J WERNER, Luc R C W VAN LONKHUIJZEN, Refika YIGIT, Camilla KRAKSTAD, Petronella O WITTEVEEN, Khadra GALAAL, Alexandra A VAN GINKEL, Eliana BIGNOTTI, Vít WEINBERGER, Sanne SWEEGERS, Ane Gerda Z ERIKSSON, Diederick M KEIZER, van de Stolpe ANJA, Andrea ROMANO and Johanna M A PIJNENBORG. Hormone Receptor Expression and Activity for Different Tumour Locations in Patients with Advanced and Recurrent Endometrial Carcinoma. Cancers. BASEL: MDPI, 2024, vol. 16, No 11, p. 1-19. ISSN 2072-6694. Available from: https://dx.doi.org/10.3390/cancers16112084.

Basic information

• Original name: Hormone Receptor Expression and Activity for Different Tumour Locations in Patients with Advanced and Recurrent Endometrial Carcinoma
• Authors: LUIJTEN, Maartje M W, van Weelden Willem JAN, Roy I LALISANG, Johan BULTEN, Kristina LINDEMANN, Heleen J VAN BEEKHUIZEN, Hans TRUM, Dorry BOLL, Henrica M J WERNER, Luc R C W VAN LONKHUIJZEN, Refika YIGIT, Camilla KRAKSTAD, Petronella O WITTEVEEN, Khadra GALAAL, Alexandra A VAN GINKEL, Eliana BIGNOTTI, Vít WEINBERGER (203 Czech Republic, belonging to the institution), Sanne SWEEGERS, Ane Gerda Z ERIKSSON, Diederick M KEIZER, van de Stolpe ANJA, Andrea ROMANO and Johanna M A PIJNENBORG.
• Edition: Cancers, BASEL, MDPI, 2024, 2072-6694.

Other information

• Original language: English
• Type of outcome: Article in a journal
• Field of Study: 30214 Obstetrics and gynaecology
• Country of publisher: Switzerland
• Confidentiality degree: is not subject to a state or trade secret
• WWW: URL
• Impact factor: Impact factor: 5.200 in 2022
• Organization unit: Faculty of Medicine
• Doi: http://dx.doi.org/10.3390/cancers16112084
• UT WoS: 001246772500001
• Keywords in English: endometrial cancer; hormone receptor; tumour location
• Tags: 14110240, rivok
• Tags: International impact, Reviewed

Abstract

Background: Response to hormonal therapy in advanced and recurrent endometrial cancer (EC) can be predicted by oestrogen and progesterone receptor immunohistochemical (ER/PR-IHC) expression, with response rates of 60% in PR-IHC > 50% cases. ER/PR-IHC can vary by tumour location and is frequently lost with tumour progression. Therefore, we explored the relationship between ER/PR-IHC expression and tumour location in EC. Methods: Pre-treatment tumour biopsies from 6 different sites of 80 cases treated with hormonal therapy were analysed for ER/PR-IHC expression and classified into categories 0-10%, 10-50%, and >50%. The ER pathway activity score (ERPAS) was determined based on mRNA levels of ER-related target genes, reflecting the actual activity of the ER receptor. Results: There was a trend towards lower PR-IHC (33% had PR > 50%) and ERPAS (27% had ERPAS > 15) in lymphogenic metastases compared to other locations (p = 0.074). Hematogenous and intra-abdominal metastases appeared to have high ER/PR-IHC and ERPAS (85% and 89% ER-IHC > 50%; 64% and 78% PR-IHC > 50%; 60% and 71% ERPAS > 15, not significant). Tumour grade and previous radiotherapy did not affect ER/PR-IHC or ERPAS. Conclusions: A trend towards lower PR-IHC and ERPAS was observed in lymphogenic sites. Verification in larger cohorts is needed to confirm these findings, which may have implications for the use of hormonal therapy in the future.